An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors

By sjmartinez • June 23, 2023

Nadres B, Momcilovic M, Shackelford DB, Lisberg A. An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors. J Thorac Oncol. 2023 Jul;18(7):847-850. doi: 10.1016/j.jtho.2023.04.012. PMID: 37348993.

Tags: Hematology/Oncology, Publications, Pulmonary, Critical Care & Sleep Medicine

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van[...]

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]